Use of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review

doi:10.1007/s13300-019-0613-7

Review

. 2019 Jun;10(3):805-833.

doi: 10.1007/s13300-019-0613-7. Epub 2019 Apr 24.

Use of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review

Takahisa Hirose¹, Ching-Chu Chen^{2

3}, Kyu Jeung Ahn⁴, Jacek Kiljański⁵

Affiliations

¹ Division of Diabetes, Metabolism and Endocrinology, Department of Medicine, Toho University Graduate School of Medicine, Tokyo, Japan.
² Division of Endocrinology and Metabolism, Department of Medicine, China Medical University Hospital, Taichung, Taiwan.
³ China Medical University School of Chinese Medicine, Taichung, Taiwan.
⁴ Department of Endocrinology and Metabolism, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea.
⁵ Eli Lilly Polska, Warsaw, Poland. kiljanski_jacek@lilly.com.

PMID: 31020538
PMCID: PMC6531539
DOI: 10.1007/s13300-019-0613-7

Review

Use of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review

Takahisa Hirose et al. Diabetes Ther. 2019 Jun.

. 2019 Jun;10(3):805-833.

doi: 10.1007/s13300-019-0613-7. Epub 2019 Apr 24.

Authors

Takahisa Hirose¹, Ching-Chu Chen^{2

3}, Kyu Jeung Ahn⁴, Jacek Kiljański⁵

Affiliations

¹ Division of Diabetes, Metabolism and Endocrinology, Department of Medicine, Toho University Graduate School of Medicine, Tokyo, Japan.
² Division of Endocrinology and Metabolism, Department of Medicine, China Medical University Hospital, Taichung, Taiwan.
³ China Medical University School of Chinese Medicine, Taichung, Taiwan.
⁴ Department of Endocrinology and Metabolism, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea.
⁵ Eli Lilly Polska, Warsaw, Poland. kiljanski_jacek@lilly.com.

PMID: 31020538
PMCID: PMC6531539
DOI: 10.1007/s13300-019-0613-7

Abstract

Insulin glargine (IGlar) 100 U/mL (IGlar-100) is widely used in East Asian countries for the treatment of type 2 diabetes mellitus (T2DM) and is the gold standard of basal insulin treatment. In this review we summarize key information about clinical experience with IGlar-100 in East Asian patients with T2DM, including findings from clinical trials and postmarketing studies. We also provide recommendations and opinions on the optimal use of IGlar-100 in this population. The findings from the studies highlighted in our review indicate that IGlar-100 can be a suitable treatment option for East Asians with T2DM, from initial therapy in combination with oral antihyperglycemic medications through to different combinations and intensification models. FUNDING: Eli Lilly and Company.

Keywords: Basal insulin; Diabetes mellitus; East Asian; Insulin glargine; Type 2.

PubMed Disclaimer

Cited by

A pragmatic study of mid-mixture insulin and basal insulin treatment in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic medications: A lesson from real-world experience.
Zhang X, Ma Y, Chen H, Lou Y, Ji L, Chen L. Zhang X, et al. Diabetes Obes Metab. 2020 Aug;22(8):1436-1442. doi: 10.1111/dom.14052. Epub 2020 May 11. Diabetes Obes Metab. 2020. PMID: 32267071 Free PMC article. Clinical Trial.
Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: DosInGlar Study.
Duque N, Artime E, Romera I, Lebrec J, Díaz S, Rubio M, Sicras-Mainar A, Carretero-Anibarro E, Mundet X, Gorgojo-Martínez JJ, Reviriego J. Duque N, et al. Adv Ther. 2021 Jul;38(7):3857-3871. doi: 10.1007/s12325-021-01773-z. Epub 2021 May 29. Adv Ther. 2021. PMID: 34052987 Free PMC article.

References

1. International Diabetes Federation. Brussels, Belgium: IDF; 2017. IDF diabetes atlas—8th edition. https://idf.org/e-library/welcome.html. Accessed 10 Jun 2018.
1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137–149. - PubMed
1. Pettus J, Santos Cavaiola T, Tamborlane WV, Edelman S. The past, present, and future of basal insulins. Diabetes Metab Res Rev. 2016;32:478–496. - PubMed
1. Rossetti P, Ampudia-Blasco FJ, Ascaso JF. Old and new basal insulin formulations: understanding pharmacodynamics is still relevant in clinical practice. Diabetes Obes Metab. 2014;16:695–706. - PubMed
1. European Medicines Agency. London, UK: EMA; 2009. Lantus summary of product characteristics; 2009 May 8. https://www.ema.europa.eu/documents/product-information/lantus-epar-prod.... Accessed 23 Jan 2018.

Publication types

Actions

LinkOut - more resources

Full Text Sources

[1] International Diabetes Federation. Brussels, Belgium: IDF; 2017. IDF diabetes atlas—8th edition. https://idf.org/e-library/welcome.html. Accessed 10 Jun 2018.

[2] International Diabetes Federation. Brussels, Belgium: IDF; 2017. IDF diabetes atlas—8th edition. https://idf.org/e-library/welcome.html. Accessed 10 Jun 2018.

[3] Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137–149. - PubMed

[4] Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137–149. - PubMed

[5] Pettus J, Santos Cavaiola T, Tamborlane WV, Edelman S. The past, present, and future of basal insulins. Diabetes Metab Res Rev. 2016;32:478–496. - PubMed

[6] Pettus J, Santos Cavaiola T, Tamborlane WV, Edelman S. The past, present, and future of basal insulins. Diabetes Metab Res Rev. 2016;32:478–496. - PubMed

[7] Rossetti P, Ampudia-Blasco FJ, Ascaso JF. Old and new basal insulin formulations: understanding pharmacodynamics is still relevant in clinical practice. Diabetes Obes Metab. 2014;16:695–706. - PubMed

[8] Rossetti P, Ampudia-Blasco FJ, Ascaso JF. Old and new basal insulin formulations: understanding pharmacodynamics is still relevant in clinical practice. Diabetes Obes Metab. 2014;16:695–706. - PubMed

[9] European Medicines Agency. London, UK: EMA; 2009. Lantus summary of product characteristics; 2009 May 8. https://www.ema.europa.eu/documents/product-information/lantus-epar-prod.... Accessed 23 Jan 2018.

[10] European Medicines Agency. London, UK: EMA; 2009. Lantus summary of product characteristics; 2009 May 8. https://www.ema.europa.eu/documents/product-information/lantus-epar-prod.... Accessed 23 Jan 2018.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Use of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review

Affiliations

Use of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources